NEW YORK Pfizer’s acquisition of Wyeth appears to be paying off for the world’s largest drug maker.
Pfizer gave an update of its pipeline for the first time since the acquisition Wednesday, showing 133 drug-development programs in stages ranging from phase 1 to registration with regulatory authorities.
“The pipeline of investigational medicines represents the strong future of Pfizer,” president Martin Mackay of PharmaTherapeutics Research and Development, a branch of Pfizer, said in a statement. “Since the closing of the Wyeth transaction late last year, we have made strategic decisions about our R&D resources, global footprint and high-priority projects. Our focus now turns to delivery of these health solutions for patients around the world.”
The pipeline includes 30 compounds for cancer, 11 for inflammatory diseases, 10 for Alzheimer’s disease and eight for pain.